Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Short Interest Update

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a large decrease in short interest in February. As of February 27th, there was short interest totaling 27,297 shares, a decrease of 47.6% from the February 12th total of 52,048 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 29,595 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 29,595 shares, the short-interest ratio is currently 0.9 days. Approximately 0.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Several research firms recently weighed in on RADX. Wall Street Zen downgraded Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, January 22nd. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a research report on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.33.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $76,000. Jane Street Group LLC purchased a new position in Radiopharm Theranostics during the fourth quarter valued at $76,000. Marex Group plc bought a new stake in Radiopharm Theranostics in the 4th quarter valued at $54,000. Finally, PNC Financial Services Group Inc. lifted its stake in Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock worth $88,000 after purchasing an additional 8,000 shares in the last quarter.

Radiopharm Theranostics Stock Down 0.6%

Shares of Radiopharm Theranostics stock opened at $4.95 on Thursday. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25. The company has a fifty day moving average of $4.99 and a 200 day moving average of $5.36.

Radiopharm Theranostics (NASDAQ:RADX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($1.58) EPS for the quarter. The firm had revenue of $0.46 million during the quarter.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.